Search Result

Results for "

gastrointestinal side effects

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Amylases (1) Apoptosis (4) Biochemical Assay Reagents (1) Cholinesterase (ChE) (1) COX (9) Drug Derivative (3) Endogenous Metabolite (1) Epoxide Hydrolase (1) Glycosidase (2) Interleukin Related (3) Isotope-Labeled Compounds (2) Lipoxygenase (1) mAChR (3) MMP (2) Monoamine Oxidase (2) NF-κB (3) Opioid Receptor (1) P-glycoprotein (1) p38 MAPK (2) Reactive Oxygen Species (ROS) (2) Reference Standards (3) TNF Receptor (3)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Endocrinology (2) Inflammation/Immunology (10) Metabolic Disease (5) Neurological Disease (11)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107111

GSK1034702	mAChR	Neurological Disease
GSK1034702 is an orally active and allosteric agonist of M1 mAChR (pEC₅₀=8.1) that can cross the blood-brain barrier. GSK1034702 activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .

HY-N1965

Gaultherin	NF-κB p38 MAPK COX Monoamine Oxidase MMP Interleukin Related TNF Receptor Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
Gaultherin is an orally active non-steroidal anti-inflammatory agent. Gaultherin selectively inhibits NF-κB, MAPK, COX-2 (IC₅₀ = 0.35 mg/mL), LOX (IC₅₀ = 0.56 mg/mL) and HYAL (IC₅₀ = 28.58 μg/mL) to exert anti-inflammatory, antipyretic and analgesic effects. Gaultherin exhibits modest direct antioxidant capacity, greater in cell-based models. Gaultherin does not affect COX-1 so that avoids the common gastrointestinal side effects of Aspirin (HY-14654) .

HY-17509

Deracoxib 1 Publications Verification SC 046; SC 46; SC 59046	COX Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Deracoxib (SC 046; SC 59046), an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas .

HY-179511

α-Glucosidase-IN-104	Glycosidase	Metabolic Disease
α-Glucosidase-IN-104 (Compound 9s) is an efficient inhibitor of α-glucosidase with an IC₅₀ of 24.32 μM. α-Glucosidase-IN-104 has a weak inhibitory effect on α-amylase and avoids gastrointestinal side effects. α-Glucosidase-IN-104 can be used for research on type 2 diabetes .

HY-17509S

Deracoxib-d3 SC 046-d₃; SC 46-d₃; SC 59046-d₃	Isotope-Labeled Compounds COX Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Deracoxib-d₃ (SC 046-d₃; SC 59046-d₃) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

HY-U00020

AU-224	Drug Derivative	Metabolic Disease
AU-224 is a benzamide derivative used as a promising gastrointestinal prokinetic agent without significant side effects.

HY-118499

Alpiropride RIV-2093	Drug Derivative	Endocrinology
Alpiropride (RIV-2093) is a metoclopramide (HY-17382) analog that is effective in reducing the gastrointestinal side effects of cancer chemotherapy drugs. In animal studies, alpiropride showed a stronger antiemetic effect than metoclopramide .

HY-19846

VRX-03011 PRX-03140 potassium salt	5-HT Receptor	Others
VRX-03011 (PRX-03140 (potassium salt)) is a compound with the potential to enhance memory and regulate acetylcholine release. It is a 5-HT? agonist that can enhance memory, regulate hippocampal acetylcholine efflux, and regulate APP metabolism without gastrointestinal side effects.

HY-159923

BPRMU191	Opioid Receptor	Neurological Disease
BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biased MOR agonists, thereby inducing MOR-dependent activation and analgesic effects. Co-administration of BPRMU191 with morphinan antagonists provides analgesia while reducing side effects such as gastrointestinal dysfunction, antinociceptive tolerance, and dependency-related adverse effects. BPRMU191, in combination with morphinan antagonists, offers a potential strategy for studying severe pain management and G protein-coupled receptor modulation .

HY-159169

5-LOX/sEH-IN-1	COX Epoxide Hydrolase Lipoxygenase	Inflammation/Immunology
5-LOX/sEH-IN-1 (Compound 8o) is a dual 5-LOX/sEH-IN-1 inhibitor with cardioprotective effects, exhibiting IC₅₀ values of 3.05 μM and 2.20 nM respectively, and 5-LOX/sEH-IN-1 can also inhibit the activity of COX-2 (IC₅₀=10.50 μM). 5-LOX/sEH-IN-1 has analgesic and anti-inflammatory effects, while reducing ulcer pathogenicity, and can be used to develop anti-inflammatory agents with fewer gastrointestinal and cardiovascular side effects .

HY-170585

COX-2-IN-51	COX NF-κB	Inflammation/Immunology
COX-2-IN-51 (E25) is a potent COX-2 inhibitor, with an IC₅₀ of 70.7 nM. COX-2-IN-51 significantly inhibits LPS-induced release of NO and PGE2, expression of COX-2 and iNOS, and activation of NF-κB pathway. COX-2-IN-51 exhibits anti-inflammatory and analgesic effects in diverse murine models through inhibiting NF-κB pathway. COX-2-IN-51 has lower gastrointestinal side effects than Indomethacin (HY-14397) .

HY-N1965R

Gaultherin (Standard)	Reference Standards NF-κB p38 MAPK COX Reactive Oxygen Species (ROS) Monoamine Oxidase MMP Interleukin Related TNF Receptor	Neurological Disease Inflammation/Immunology
Gaultherin (Standard) is the analytical standard for Gaultherin (HY-N1965). Gaultherin is an orally active non-steroidal anti-inflammatory agent. Gaultherin selectively inhibits NF-κB, MAPK, COX-2 (IC₅₀ = 0.35 mg/mL), LOX (IC₅₀ = 0.56 mg/mL) and HYAL (IC₅₀ = 28.58 μg/mL) to exert anti-inflammatory, antipyretic and analgesic effects. Gaultherin exhibits modest direct antioxidant capacity, greater in cell-based models. Gaultherin does not affect COX-1 so that avoids the common gastrointestinal side effects of Aspirin (HY-14654) .

HY-162373

α-Amylase/α-Glucosidase-IN-10	Amylases Glycosidase P-glycoprotein	Metabolic Disease
α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC₅₀: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .

HY-107111A

GSK1034702 hydrochloride	Cholinesterase (ChE) mAChR	Neurological Disease
GSK1034702 hydrochloride is an orally active and allosteric agonist of M1 mAChR (pEC₅₀=8.1) that can cross the blood-brain barrier. GSK1034702 hydrochloride activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 hydrochloride can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 hydrochloride can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .

HY-17509R

Deracoxib (Standard) SC 046 (Standard); SC 46 (Standard); SC 59046 (Standard)	Reference Standards COX Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Deracoxib (SC 046; SC 59046) (Standard) is the analytical standard of Deracoxib (HY-17509). This product is intended for research and analytical applications. Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas

HY-W703540

Deracoxib-d4 SC 046-d₄; SC 46-d₄; SC 59046-d₄	Isotope-Labeled Compounds Apoptosis COX	Neurological Disease Inflammation/Immunology Cancer
Deracoxib-d₄ (SC 046-d₄; SC 59046--d₄) is deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

HY-16778

Etiguanfacine	Drug Derivative	Neurological Disease Metabolic Disease Endocrinology
Etiguanfacine is a derivative of Guanfacine (HY-17416A). Etiguanfacine can be used for research to reduce the gastrointestinal side effects of Guanfacine .

HY-119200

LY-195448 hydrochloride	Endogenous Metabolite	Cancer
LY-195448 hydrochloride is a phenethanolamine that exhibits anti-tumour activity across various murine tumour models. LY-195448 hydrochloride acts by blocking cells at metaphase. LY-195448 hydrochloride has demonstrated a lack of "standard" side effects commonly associated with cancer treatments, such as myelosuppression and gastrointestinal toxicity. LY-195448 hydrochloride was evaluated in a phase I trial, where it showed only mild and reversible side effects like hypotension, tachycardia, and tremor.

HY-124470

Amisometradine	Others	Cardiovascular Disease
Amisometradine is an orally active aminouracil diuretic with a diuretic potency approximately 40% that of Mersalyl (HY-108868) (when administered intramuscularly). Amisometradine exerts its effects by promoting the excretion of sodium, chloride and a small amount of potassium, exhibits significant therapeutic effects in heart failure models, and has good tolerance with long-term administration. Compared with drugs of the same class, Amisometradine causes fewer gastrointestinal reactions; its minor side effects mainly include nausea, vomiting, diarrhea, tinnitus and deafness, and are usually not accompanied by proteinuria or abnormalities in blood and urine indicators. Amisometradine is an important tool for the study of heart failure and related diuretic mechanisms .

HY-180822

COX-2-IN-63	COX TNF Receptor Interleukin Related	Inflammation/Immunology
COX-2-IN-63 (Compound 6k) is an orally active COX-2 inhibitor with an IC₅₀ of 0.89 μM. COX-2-IN-63 reduces the levels of inflammatory mediators PGE2, TNF-α, and IL-6. COX-2-IN-63 can effectively alleviate acute inflammation in a rat paw edema model and has a lower risk of gastrointestinal side effects. COX-2-IN-63 can be used in anti-inflammatory research .

HY-107111R

GSK1034702 (Standard)	Reference Standards mAChR	Neurological Disease
GSK1034702 (Standard) is the analytical standard of GSK1034702 (HY-107111). This product is intended for research and analytical applications. GSK1034702 is an orally active and allosteric agonist of M1 mAChR (pEC₅₀=8.1) that can cross the blood-brain barrier. GSK1034702 activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .

HY-118418

Anti-inflammatory agent 120	Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology
Anti-inflammatory agent 120 is an orally active non-steroidal anti-inflammatory agent. Anti-inflammatory agent 120 can be used in the research of rheumatoid arthritis, osteoarthritis, dysmenorrhea, acute gouty arthritis, ankylosing spondylitis and dementia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1965

Gaultherin	other families Classification of Application Fields Ketones, Aldehydes, Acids Gaultheria yunnanensis Ericaceae Plants Inflammation/Immunology Disease Research Fields Source Classification	NF-κB p38 MAPK COX Monoamine Oxidase MMP Interleukin Related TNF Receptor Reactive Oxygen Species (ROS)
Gaultherin is an orally active non-steroidal anti-inflammatory agent. Gaultherin selectively inhibits NF-κB, MAPK, COX-2 (IC₅₀ = 0.35 mg/mL), LOX (IC₅₀ = 0.56 mg/mL) and HYAL (IC₅₀ = 28.58 μg/mL) to exert anti-inflammatory, antipyretic and analgesic effects. Gaultherin exhibits modest direct antioxidant capacity, greater in cell-based models. Gaultherin does not affect COX-1 so that avoids the common gastrointestinal side effects of Aspirin (HY-14654) .

HY-N1965R

Gaultherin (Standard)	Structural Classification other families Ketones, Aldehydes, Acids Gaultheria yunnanensis Ericaceae Plants Source Classification	Reference Standards NF-κB p38 MAPK COX Reactive Oxygen Species (ROS) Monoamine Oxidase MMP Interleukin Related TNF Receptor
Gaultherin (Standard) is the analytical standard for Gaultherin (HY-N1965). Gaultherin is an orally active non-steroidal anti-inflammatory agent. Gaultherin selectively inhibits NF-κB, MAPK, COX-2 (IC₅₀ = 0.35 mg/mL), LOX (IC₅₀ = 0.56 mg/mL) and HYAL (IC₅₀ = 28.58 μg/mL) to exert anti-inflammatory, antipyretic and analgesic effects. Gaultherin exhibits modest direct antioxidant capacity, greater in cell-based models. Gaultherin does not affect COX-1 so that avoids the common gastrointestinal side effects of Aspirin (HY-14654) .

Cat. No.	Product Name	Chemical Structure

HY-17509S

Deracoxib-d3
Deracoxib-d₃ (SC 046-d₃; SC 59046-d₃) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

Deracoxib-d3

Deracoxib-d₃ (SC 046-d₃; SC 59046-d₃) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

HY-W703540

Deracoxib-d4
Deracoxib-d₄ (SC 046-d₄; SC 59046--d₄) is deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

Deracoxib-d4

Deracoxib-d₄ (SC 046-d₄; SC 59046--d₄) is deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.

Cat. No.	Product Name		Classification

HY-159169

5-LOX/sEH-IN-1		Azide
5-LOX/sEH-IN-1 (Compound 8o) is a dual 5-LOX/sEH-IN-1 inhibitor with cardioprotective effects, exhibiting IC₅₀ values of 3.05 μM and 2.20 nM respectively, and 5-LOX/sEH-IN-1 can also inhibit the activity of COX-2 (IC₅₀=10.50 μM). 5-LOX/sEH-IN-1 has analgesic and anti-inflammatory effects, while reducing ulcer pathogenicity, and can be used to develop anti-inflammatory agents with fewer gastrointestinal and cardiovascular side effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks